Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Saniona publishes its year-end report for 2020
Saniona ABMarch 17, 2021 GMT
PRESS RELEASE Revenue was SEK 8.2 M (7.2 M) Operating loss was SEK -159.4 (-93.6 M) Net loss was SEK -73.4 M (-68.8 M) Earnings per share were SEK -1.79 (-2.67) Diluted earnings per share were SEK -1.75 (-2.67)
Q4 2020 (Q4 2019 restated) Revenue was SEK 1.6 M (0.0 M) Operating loss was SEK -68.8 M (-28.2 M) Net loss was SEK -45.6 M (-6.8 M) Earnings per share were SEK -0.73 (-0.24) Diluted earnings per share were SEK -0.73 (-0.24)
Saniona publishes its year-end report for 2020 globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Baxter BioPharma Solutions And Moderna Announce Agreement For Fill/Finish Manufacturing Of Moderna COVID-19 Vaccine In USA
Agreement to perform fill/finish services for approximately 60–90 million doses in the U.S. this year
Manufacturing will take place at Baxter BioPharma Solutions’ Indiana facility
Baxter International Inc. a global leader in sterile medication production and delivery, and Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that they have entered into an agreement for Baxter BioPharma Solutions to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. Baxter’s BioPharma Solutions business is a premier contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals, including vaccines.
December 21, 2020
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the further expansion of its executive team with the appointments of Denelle Waynick as Chief Legal Officer and Kyle
Haraldsen as Chief Technical Operations Officer. The positions will be based in the U.S. and will support Saniona’s advancement of clinical trials for Tesomet and SAN711 as well as the company’s growing U.S. presence.
“This has been a year of transformation for Saniona, evolving from a company focused on early-stage research to one capable of conducting its own mid-stage clinical trials. As we close out 2020, the hiring of Denelle and Kyle completes Saniona’s executive team in support of our current business,” said Rami Levin, President and CEO of Saniona. “As we look to 2021, our entire organization is focused on initiating Phase 2b clinical trials of Tesomet in HO and PWS, as well as advancing SAN711, the first drug candidate
Saniona AB: Saniona Appoints Chief Legal Officer and Chief Technical Operations Officer to Its Executive Team
December 21, 2020
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the further expansion of its executive team with the appointments of Denelle Waynick as Chief Legal Officer and Kyle
Haraldsen as Chief Technical Operations Officer. The positions will be based in the U.S. and will support Saniona s advancement of clinical trials for Tesomet and SAN711 as well as the company s growing U.S. presence. This has been a year of transformation for Saniona, evolving from a company focused on early-stage research to one capable of conducting its own mid-stage clinical trials. As we close out 2020, the hiring of Denelle and Kyle completes Saniona s executive team in support of our current business, said Rami Levin, President and CEO of Saniona. As we look to 2021, our entire organization is focused on initiating Phase 2